Sitagliptin Export Market Intelligence: India's 309 Suppliers Shipping to 121 Countries — TransData Nexus 2026

Q: Who are the top sitagliptin exporters from India?

The top sitagliptin exporters from India are: 1. DR.REDDY'S LABORATORIES LTD — $7.7M (10.2% market share); 2. SANDOZ PRIVATE LIMITED — $7.6M (10.0% market share); 3. MYLAN LABORATORIES LIMITED — $7.0M (9.2% market share); 4. HETERO LABS LIMITED — $5.8M (7.6% market share); 5. FREDUN PHARMACEUTICALS LTD — $5.1M (6.8% market share). Together they account for 43.8% of India's total sitagliptin export value.

Q: What is the total export value of sitagliptin from India?

The total export value of sitagliptin from India is $75.8M USD, recorded across 5,364 shipment transactions from 309 active exporters to 121 destination countries. The average shipment value is $14.1K.

Q: Which countries import sitagliptin from India?

India exports sitagliptin to 121 countries worldwide. The top importing countries are: CANADA (11.6% share, $8.8M), MEXICO (11.1% share, $8.4M), PHILIPPINES (9.7% share, $7.3M), GERMANY (9.0% share, $6.9M), UNITED KINGDOM (7.6% share, $5.8M). These five markets account for 49.0% of total export value.

Q: What is the HS code for sitagliptin exports from India?

The primary HS code for sitagliptin exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of sitagliptin exports from India?

The average unit price for sitagliptin exports from India is $6.29 USD per unit, with prices ranging from $0.00 to $2133.63 depending on formulation, packaging, and order volume. The total market is valued at $75.8M across 5,364 shipments.

Q: Which ports handle sitagliptin exports from India?

The primary ports for sitagliptin exports from India are SAHAR AIR CARGO ACC (INBOM4) (14.4% of shipments), DELHI AIR CARGO ACC (INDEL4) (13.8% of shipments), SAHAR AIR (13.7% of shipments), DELHI AIR (9.6% of shipments), NHAVA SHEVA SEA (INNSA1) (4.0% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of sitagliptin?

India is one of the world's leading exporters of sitagliptin due to its large base of 309 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports sitagliptin to 121 countries, demonstrating 62% global market coverage.

Q: What certifications do Indian sitagliptin exporters need?

Indian sitagliptin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import sitagliptin from India?

There are 575 registered buyers importing sitagliptin from India, spread across 121 countries. The repeat buyer rate is 68.9%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top sitagliptin supplier from India?

DR.REDDY'S LABORATORIES LTD is the leading sitagliptin exporter from India with a market share of 10.2% and total export value of $7.7M across 243 shipments. The top 5 suppliers together control 43.8% of total export value.

Suresh Sormare

Sitagliptin

India Pharmaceutical Trade Intelligence

$75.8M309 Suppliers121 CountriesHS 30049099

ExportsIndia → CANADA11.6%India → MEXICO11.1%

ImportsCANADA → India$43.8K NETHERLANDS → India$23.2K

#1 Buyer: YILMAZ TRANSPORT

Sitagliptin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Sitagliptin to the World

Between 2022 and 2026, India exported $75.8M worth of sitagliptin across 5,364 verified shipments to 121 countries — covering 62% of world markets in the Diabetes & Endocrine segment. The largest destination is CANADA (11.6%). DR.REDDY'S LABORATORIES LTD leads with a 10.2% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published May 2026·Updated May 2026·

Sitagliptin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Sitagliptin export data snapshot — $75.8M · 309 exporters · 121 countriesTransData Nexus · Indian Customs Data

Top Sitagliptin Exporters from India

309 active exporters · Ranked by export value

View all 309 →

Top Sitagliptin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	DR.REDDY'S LABORATORIES LTD	$7.7M	243	8	10.2%
2	SANDOZ PRIVATE LIMITED

Top Countries Importing Sitagliptin from India

121 destination markets · Ranked by import value

All 121 countries →

Top Countries Importing Sitagliptin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	CANADA	$8.8M	11.6%
2	MEXICO	$8.4M	11.1%
3	PHILIPPINES	$7.3M	9.7%
4	GERMANY	$6.9M	9.0%
5	UNITED KINGDOM	$5.8M	7.6%
6	IRAQ	$5.5M	7.2%
7	NETHERLANDS	$4.5M	5.9%
8	MALTA	$4.4M	5.8%
9	FRANCE	$4.3M	5.7%
10	SAUDI ARABIA	$3.2M	4.3%

CANADA is India's largest sitagliptin export destination, absorbing 11.6% of total exports worth $8.8M. The top 5 importing countries — CANADA, MEXICO, PHILIPPINES, GERMANY, UNITED KINGDOM — together account for 49.0% of India's total sitagliptin export value. The remaining 116 destination countries collectively receive the other 51.0%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Sitagliptin to India?

32 origin countries · Total import value: $119.1M

India imports sitagliptin from 32 countries with a combined import value of $119.1M. The largest supplier is SPAIN ($111.2M, 67 shipments), followed by UNITED STATES and PUERTO RICO. All values are from Indian Customs (DGFT) import records.

Countries Supplying Sitagliptin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	SPAIN	$111.2M	67	93.4%
2	UNITED STATES	$7.3M	187	6.2%
3	PUERTO RICO	$319.5K	6	0.3%
4	CANADA	$43.8K	50	0.0%
5	NETHERLANDS	$23.2K	41	0.0%
6	GERMANY	$21.4K	37	0.0%
7	UNITED KINGDOM	$16.8K	23	0.0%
8	JAPAN	$15.7K	11	0.0%
9	ITALY	$14.9K	9	0.0%
10	SINGAPORE	$12.0K	10	0.0%

Showing top 10 of 32 origin countries

SPAIN is the largest supplier of sitagliptin to India, accounting for 93.4% of total import value. The top 5 origin countries — SPAIN, UNITED STATES, PUERTO RICO, CANADA, NETHERLANDS — together supply 99.9% of India's sitagliptin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Sitagliptin — Export Intelligence Video

Visual overview of India's sitagliptin import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's sitagliptin pharmaceutical import and export market — $75.8M in total trade, 309 verified manufacturers, and 121 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Sitagliptin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, Sitagliptin is approved for the treatment of type 2 diabetes mellitus. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Sitagliptin, indicating the presence of generic versions in the market. The regulatory pathway for Sitagliptin involves demonstrating bioequivalence to the reference listed drug, ensuring safety and efficacy. As of March 2026, there are no active FDA import alerts specifically targeting Sitagliptin, suggesting compliance with U.S. regulatory standards. Given that 309 Indian exporters are active in the Sitagliptin market, adherence to FDA regulations is crucial for maintaining market access.

2EU & UK Regulatory Framework

In the European Union, Sitagliptin has been subject to marketing authorizations by the European Medicines Agency (EMA). For instance, Sitagliptin/Metformin Hydrochloride Accord received marketing authorization on July 22, 2022. However, this authorization ceased to be valid on July 22, 2025, as the product was not marketed within three years of approval, invoking the EU's "sunset clause" provisions. This underscores the importance of timely market entry post-authorization. The United Kingdom, post-Brexit, follows its own regulatory framework under the Medicines and Healthcare products Regulatory Agency (MHRA), which aligns closely with EMA standards. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for market access in both regions.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) includes Sitagliptin in its Model List of Essential Medicines, recognizing its importance in managing type 2 diabetes mellitus. The 24th edition of the WHO Model List, published in September 2025, lists Sitagliptin as an essential medicine. This inclusion emphasizes the global recognition of Sitagliptin's therapeutic value. Manufacturers are expected to comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product quality and consistency.

4India Regulatory Classification

In India, Sitagliptin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drug Price Control Order (DPCO). As of March 2026, Sitagliptin is subject to price control measures to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring that domestic needs are met before permitting exports.

5Patent & Exclusivity Status

The primary patent for Sitagliptin has expired, allowing for the introduction of generic versions into the market. This has led to increased competition among manufacturers, including Indian exporters, contributing to the availability of cost-effective generic Sitagliptin globally.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of Sitagliptin due to its efficacy in managing type 2 diabetes mellitus. In July 2025, the EMA announced the cessation of validity for the marketing authorization of Sitagliptin/Metformin Hydrochloride Accord, highlighting the critical importance of timely market entry post-authorization. In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, continuing to list Sitagliptin as an essential medicine, underscoring its global therapeutic significance. In January 2026, the WHO released a fact sheet on essential medicines, emphasizing the need for these medicines to be available, affordable, and of assured quality at all times, reinforcing the importance of compliance with international standards for Sitagliptin manufacturers. In February 2026, the WHO published the report of the 25th Expert Committee on Selection and Use of Essential Medicines, providing detailed insights into the selection process and reaffirming the inclusion of Sitagliptin in the Model List.

These developments highlight the dynamic regulatory landscape for Sitagliptin, emphasizing the need for manufacturers and exporters to stay informed and compliant with international standards and regulations.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Sitagliptin

Retail & reference prices across 9 markets vs. India FOB export price of $6.29/unit

Global Price Benchmark for Sitagliptin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$2.98	USD	According to the National Center for Biotechnology Information (NCBI), the average price for Sitagliptin 100 mg is $2.98 per tablet.
United Kingdom	$3.25	GBP	The National Institute for Health and Care Excellence (NICE) lists the price of Sitagliptin 100 mg at £2.50 per tablet.
Germany	$3.30	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) provides this pricing information.
Australia	$2.80

Supply Chain Risk Assessment — Sitagliptin

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Sitagliptin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities, particularly when Chinese manufacturing faces disruptions due to environmental regulations or geopolitical tensions. For instance, in July 2018, stringent environmental policies led to the shutdown of several Chinese chemical plants, causing supply shortages and price escalations for Indian pharmaceutical companies.

To mitigate this dependency, the Indian government launched the Production Linked Incentive (PLI) scheme in 2020, aiming to bolster domestic API and KSM manufacturing. By November 2024, two greenfield plants were inaugurated under this scheme to produce critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import reliance. However, the effectiveness of these initiatives in achieving self-sufficiency remains to be fully realized.

2Supplier Concentration & Single-Source Risk

Our proprietary data indicates that the top five exporters of Sitagliptin from India account for 43.8% of the total export value, with Dr. Reddy's Laboratories Ltd. leading at a 10.2% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges. The PLI scheme, while primarily targeting API and KSM production, indirectly supports finished pharmaceutical exports by strengthening the upstream supply chain. As of December 2025, the scheme has attracted significant investments, with 22 greenfield manufacturing projects commissioned, enhancing India's capacity to produce essential medical devices and pharmaceuticals.

Access Complete Sitagliptin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 5,364 transactions across 121 markets.

Request Demo View Pricing

Frequently Asked Questions — Sitagliptin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top sitagliptin exporters from India?

The leading sitagliptin exporters from India are DR.REDDY'S LABORATORIES LTD, SANDOZ PRIVATE LIMITED, MYLAN LABORATORIES LIMITED, and 12 others. DR.REDDY'S LABORATORIES LTD leads with 10.2% market share ($7.7M). The top 5 suppliers together control 43.8% of total export value.

What is the total export value of sitagliptin from India?

The total export value of sitagliptin from India is $75.8M, recorded across 5,364 shipments from 309 active exporters to 121 countries. The average shipment value is $14.1K.

Which countries import sitagliptin from India?

India exports sitagliptin to 121 countries. The top importing countries are CANADA (11.6%), MEXICO (11.1%), PHILIPPINES (9.7%), GERMANY (9.0%), UNITED KINGDOM (7.6%), which together account for 49.0% of total export value.

What is the HS code for sitagliptin exports from India?

The primary HS code for sitagliptin exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Sitagliptin

Sitagliptin

Top Sitagliptin Exporters from India

Top Countries Importing Sitagliptin from India

Who Supplies Sitagliptin to India?

Quick Facts

Related Diabetes & Endocrine

Related Analysis

Need Details?

Sitagliptin — Export Intelligence Video

Regulatory Landscape — Sitagliptin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Sitagliptin

Supply Chain Risk Assessment — Sitagliptin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Sitagliptin Trade Intelligence

Frequently Asked Questions — Sitagliptin Exports from India

Who are the top sitagliptin exporters from India?

What is the total export value of sitagliptin from India?

Which countries import sitagliptin from India?

What is the HS code for sitagliptin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of sitagliptin exports from India?

Which ports handle sitagliptin exports from India?

Why is India a leading exporter of sitagliptin?

What certifications do Indian sitagliptin exporters need?

How many buyers import sitagliptin from India?

What is the market share of the top sitagliptin exporter from India?

Analysis Methodology